Terms: = Ovarian cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
41 results:
1. cxcr4-directed PET/CT with [
Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
[TBL] [Abstract] [Full Text] [Related]
2. Tissue Expression and Prognostic Role of CXCL12 and cxcr4 in High-grade Serous ovarian Carcinoma.
Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
[TBL] [Abstract] [Full Text] [Related]
3. The role of selected molecular factors in ovarian cancer metastasis.
Markowska A; Sawicki W; Zurawski J; Fechner J; Markowska J
Ginekol Pol; 2022; 93(8):670-674. PubMed ID: 35894484
[TBL] [Abstract] [Full Text] [Related]
4. cxcr4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Zi D; Li Q; Xu CX; Zhou ZW; Song GB; Hu CB; Wen F; Yang HL; Nie L; Zhao X; Tan J; Zhou SF; He ZX
Aging (Albany NY); 2022 Jun; 14(11):4673-4698. PubMed ID: 35681259
[TBL] [Abstract] [Full Text] [Related]
5. Effect of bevacizumab combined with chemotherapy on SDF-1 and cxcr4 in epithelial ovarian cancer and its prognosis.
Ma C
World J Surg Oncol; 2022 May; 20(1):154. PubMed ID: 35545781
[TBL] [Abstract] [Full Text] [Related]
6. Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients.
Fei H; Chen S; Xu C
J Ovarian Res; 2021 Mar; 14(1):41. PubMed ID: 33676525
[TBL] [Abstract] [Full Text] [Related]
7. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
8. Integrative analysis of the common genetic characteristics in ovarian cancer stem cells sorted by multiple approaches.
Zhang X; Su Y; Wu X; Xiao R; Wu Y; Yang B; Wang Z; Guo L; Kang X; Wang C
J Ovarian Res; 2020 Sep; 13(1):116. PubMed ID: 32977853
[TBL] [Abstract] [Full Text] [Related]
9. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
Gong G; Lin T; Yuan Y
J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
[TBL] [Abstract] [Full Text] [Related]
10. Pharmacological blockage of the cxcr4-CXCL12 axis in endometriosis leads to contrasting effects in proliferation, migration, and invasion.
Ruiz A; Ruiz L; Colón-Caraballo M; Torres-Collazo BJ; Monteiro JB; Bayona M; Fazleabas AT; Flores I
Biol Reprod; 2018 Jan; 98(1):4-14. PubMed ID: 29161347
[TBL] [Abstract] [Full Text] [Related]
11. A Role for cxcr4 in Peritoneal and Hematogenous ovarian cancer Dissemination.
Figueras A; Alsina-Sanchís E; Lahiguera Á; Abreu M; Muinelo-Romay L; Moreno-Bueno G; Casanovas O; Graupera M; Matias-Guiu X; Vidal A; Villanueva A; Viñals F
Mol Cancer Ther; 2018 Feb; 17(2):532-543. PubMed ID: 29146630
[TBL] [Abstract] [Full Text] [Related]
12. cxcr4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
Reeves PM; Abbaslou MA; Kools FRW; Poznansky MC
Anticancer Drugs; 2017 Oct; 28(9):935-942. PubMed ID: 28817386
[TBL] [Abstract] [Full Text] [Related]
13. Low-dose cisplatin-induced cxcr4 expression promotes proliferation of ovarian cancer stem-like cells.
Chen Y; Wang S; Bu S; Xu M; Lai D
Acta Biochim Biophys Sin (Shanghai); 2016 Mar; 48(3):282-9. PubMed ID: 26819076
[TBL] [Abstract] [Full Text] [Related]
14. Novel role for NFAT3 in ERK-mediated regulation of cxcr4.
Huang K; Kiefer C; Kamal A
PLoS One; 2014; 9(12):e115249. PubMed ID: 25514788
[TBL] [Abstract] [Full Text] [Related]
15. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.
Yu ZH; Liu T; Zhao YH; Huang YY; Gao YT
Tumour Biol; 2014 May; 35(5):4637-44. PubMed ID: 24408020
[TBL] [Abstract] [Full Text] [Related]
16. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.
Xue B; Wu W; Huang K; Xie T; Xu X; Zhang H; Qi C; Ge J; Yu Y
Mol Cell Biochem; 2013 Aug; 380(1-2):177-84. PubMed ID: 23615713
[TBL] [Abstract] [Full Text] [Related]
17. Imaging CXCL12-cxcr4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract] [Full Text] [Related]
18. Adenovirus-mediated transcriptional targeting of colorectal cancer and effects on treatment-resistant hypoxic cells.
Rajendran S; O'Sullivan GC; O'Hanlon D; Tangney M
Clin Colorectal Cancer; 2013 Sep; 12(3):152-162.e1. PubMed ID: 23313233
[TBL] [Abstract] [Full Text] [Related]
19. Expression of angiogenic chemokines in ovarian clear cell carcinoma.
Quattrocchi L; Sisson M; Green A; Martin SG; Durrant L; Deen S
J Obstet Gynaecol Res; 2013 Jan; 39(1):297-304. PubMed ID: 22845872
[TBL] [Abstract] [Full Text] [Related]
20. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-cxcr4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract] [Full Text] [Related]
[Next]
